Cartesian Therapeutics, Inc.
RNACAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 12, 2026 | H.C. Wainwright | $25.00(+193%) | $8.53 | TheFly | |
| Mar 9, 2026 | Cantor Fitzgerald | $16.00(+77%) | $9.02 | TheFly | |
| Aug 9, 2024 | H.C. Wainwright | Mitchell Kapoor | $45.00(+250%) | $12.87 | TheFly |
| Jul 3, 2024 | Canaccord Genuity | John Newman | $43.00(+173%) | $15.77 | TheFly |
| May 24, 2024 | Mizuho Securities | Uy Ear | $40.00(+57%) | $25.46 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 30, 2026 |
| Needham | maintain | Buy | Sep 29, 2026 |
| Wedbush | maintain | Outperform | Aug 18, 2026 |
| Wedbush | maintain | Outperform | Jun 10, 2026 |
| Needham | maintain | Buy | Jun 9, 2026 |
| BTIG | maintain | Buy | Jun 9, 2026 |
| Wedbush | maintain | Outperform | May 27, 2026 |
| Needham | maintain | Buy | May 26, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 12, 2026 |
| Wedbush | maintain | Outperform | May 1, 2026 |
| Wedbush | maintain | Outperform | Mar 10, 2026 |
| Cantor Fitzgerald | upgrade | Neutral →Overweight | Mar 9, 2026 |
| Needham | maintain | Buy | Mar 9, 2026 |
| Needham | maintain | Buy | Jan 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 19, 2025 |
| BTIG | maintain | Buy | Nov 14, 2025 |
| Needham | maintain | Buy | May 8, 2025 |
| Needham | maintain | Buy | Apr 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 14, 2025 |
| Needham | maintain | Buy | Mar 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 28, 2025 |
| Needham | maintain | Buy | Jan 27, 2025 |
| Needham | maintain | Buy | Jan 13, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 4, 2024 |
Earnings History
Next report: Mar 8, 2027 · EPS est. $-1.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.38 | $-1.01 | — | $160.0K |
| Aug 6, 2026 | $0.46 | $-0.88 | — | $179.7K |
| Apr 30, 2026 | $-1.46 | $-0.84 | $78.0K | $219.8K |
| Mar 9, 2026 | $-1.38 | $-0.82 | $947.0K | $150.3K |
| Nov 6, 2025 | $-1.38 | $-0.81 | $452.0K | $266.3K |
| Aug 7, 2025 | $0.50 | $-0.76 | $298.0K | $928.6K |
| May 8, 2025 | $-0.68 | $-0.61 | $1.1M | $916.7K |
| Mar 20, 2025 | $-0.59 | $-0.78 | $759.0K | $1.0M |
News
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 Retreatment data for Descartes-08 in MG showed deep and durable responses, with a mean 6.6-point MG Activities of Daily Living (MG-ADL) reduction from baseline at Month 12 with no new safety signals Phase 2 TRITON trial of Descartes-08 in myositis and Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatom…
FREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee.
Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in AChR Ab+ Myasthenia Gravis are expected in Q1 2027, with a potential BLA filing in mid-2027. RNAC is expanding Descartes-08 into myositis indications and pursuing an in vivo CAR-T approach via a strategic WestGene licensing agreement, with initial data in H1 2027.
Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability. Volatility and Risk Syndax Pharmaceuticals has a
FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company's common stock with an exercise price of $7.22, the closing trading price of the Company's common s…
Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment
FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees.
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: